RxDoctor Payments Data

Alyssa Mabry, OD

Optometrist · Senatobia, MSNPI 1770060295

Payments from drug & device makers

What this record shows

This record is dominated by other: $65,649 of the $65,885 with a category attached, or 99.6%. Optos, Inc. accounts for 99.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $65,649 and has fallen 99.7% since, to $213 in 2025. Among optometrist clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$65,885in general payments, 2019–2025

Across 9 payments — averaging $7320.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optos, Inc.$66K
  • Biotissue Holdings Inc.$99
  • Alcon$37
  • Bausch & Lomb Americas Inc.$33
  • Glaukos Corporation$23
  • AbbVie$21

What the payments were for

  • Food & beverage$2360%
  • Other$65,649100%

General payments by program year

20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,885 in reported general payments places this provider in the 95th percentile of 372 optometrist providers in Mississippi.

See all optometrist providers in Mississippi

Medicare billing

Part B allowed, 2024
$30,830
Medicare patients
191
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost24$6,105
CombiganBrimonidine Tartrate/Timolol17$3,340
Brimonidine Tartrate15$933
Latanoprost77$610
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat24$476
Prednisolone Acetate11$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$21$9,44541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 372 optometrist providers in Mississippi.

Other optometrist in Senatobia

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →